Workflow
North American Financial 15 Split Corp. Announces TSX Acceptance of Normal Course Issuer Bid
GlobeNewswire· 2025-05-29 11:30
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on June 2, 2025 and terminate on June 1, 2026. Pursuant to the NCIB, the Company proposes to purchase, from time to ...
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
GlobeNewswire· 2025-05-29 11:30
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET. A live webcast will be available in the Invest ...
MariMed’s Premium Nature’s Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDose
GlobeNewswire· 2025-05-29 11:30
All-Natural Line of Wellness Products Designed to Support Overall Well-Being Now Available in MassachusettsNORWOOD, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), the company behind the award-winning flower and concentrate brand, Nature’s Heritage™, continued to drive innovation with the launch of MycroDose by Nature’s Heritage, a vegan line of all-natural wellness products that combine the power of full-spectrum cannabis with the added benefits of functional mus ...
Financial 15 Split Corp. Announces TSX Acceptance of Normal Course Issuer Bid
GlobeNewswire· 2025-05-29 11:30
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Financial 15 Split Corp. (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on June 2, 2025 and terminate on June 1, 2026. Pursuant to the NCIB, the Company proposes to purchase, from time to time, if it is ...
Dividend 15 Split Corp. II Announces TSX Acceptance of Normal Course Issuer Bid
GlobeNewswire· 2025-05-29 11:30
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. II (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on June 2, 2025 and terminate on June 1, 2026. Pursuant to the NCIB, the Company proposes to purchase, from time to time, if it ...
Dividend 15 Split Corp. Announces TSX Acceptance of Normal Course Issuer Bid
GlobeNewswire· 2025-05-29 11:30
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on June 2, 2025 and terminate on June 1, 2026. Pursuant to the NCIB, the Company proposes to purchase, from time to time, if it is ...
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
GlobeNewswire· 2025-05-29 11:30
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (“CMO”), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company’s Board of Directors (“Board”). Dr. C ...
Canadian Life Companies Split Corp. Announces TSX Acceptance of Normal Course Issuer Bid
GlobeNewswire· 2025-05-29 11:30
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Canadian Life Companies Split Corp. (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on June 2, 2025 and terminate on June 1, 2026. Pursuant to the NCIB, the Company proposes to purchase, from time to tim ...
Canadian Banc Corp. Announces TSX Acceptance of Normal Course Issuer Bid
GlobeNewswire· 2025-05-29 11:30
Core Viewpoint - Canadian Banc Corp. has announced its intention to initiate a Normal Course Issuer Bid (NCIB) to repurchase its Preferred Shares and Class A Shares, starting June 2, 2025, and ending June 1, 2026 [1]. Group 1: NCIB Details - The company plans to buy up to 3,742,582 Preferred Shares and 3,778,760 Class A Shares, which represents 10% of the public float of 37,425,824 Preferred Shares and 37,787,604 Class A Shares [2]. - As of May 21, 2025, there were 37,448,395 Preferred Shares and 37,821,364 Class A Shares issued and outstanding [2]. - The company will limit its purchases to a maximum of 748,967 Preferred Shares and 756,427 Class A Shares in any 30-day period, equating to 2% of the issued and outstanding shares as of May 21, 2025 [2]. Group 2: Board's Perspective - The Board of Directors, advised by Quadravest Capital Management Inc., believes that the share repurchases are in the best interests of the company and represent a desirable use of its funds [3]. - All repurchased shares will be cancelled following the NCIB [3]. Group 3: Investment Portfolio - The company invests in a portfolio of six publicly traded Canadian banks, which include Bank of Montreal, Canadian Imperial Bank of Commerce, Royal Bank of Canada, The Bank of Nova Scotia, National Bank of Canada, and The Toronto-Dominion Bank [4].
BOS Reports Record $15 Million in Revenues for the First Quarter of 2025
GlobeNewswire· 2025-05-29 11:30
RISHON LE ZION, Israel, May 29, 2025 (GLOBE NEWSWIRE) -- BOS Better Online Solutions Ltd. ("BOS" or the "Company") (NASDAQ: BOSC) reported its financial results for the first quarter of the year 2025. First Quarter 2025 Financial Highlights: Revenues increased by 33.1% to $15.0 million from $11.3 million in the first quarter of the year 2024;Gross profit margin improved to 23.9% compared to 22.7% in the first quarter of the year 2024;EBITDA increased by 86.2% to $1.9 million compared to $1.0 million in the ...